Companies

Natco Pharma seeks approval for Molnupiravir capsules for Covid-19 treatment

PTI Hyderabad | Updated on April 26, 2021

American pharma major Merck along with Ridgeback Bio therapeutics has developed the drug

Natco Pharma Limited on Monday said it applied to the Central Drugs Standard Control Organisation (CDSCO) for approval of Phase-III clinical trial of Molnupiravir Capsules for the treatment of Covid-19 positive patients.

American pharma major Merck along with Ridgeback Bio therapeutics has developed Molnupiravir(MK-4482).

According to a press release from the city-based drug maker, pre-clinical data have shown that Molnupiravir has broad anti-influenza activity, including highly potent inhibition of SARS-CoV-2 replication.

"Patients treated with Molnupiravir achieved response within 5 days of therapy indicating that the duration of treatment with Molnupiravir is short, with the additional advantage of being an oral therapy," it said.

NATCO is hoping that CDSCO would give emergency approval of this drug based on "compassionate use" for patients.

"Compassionate use" approval is given for investigational drugs so that a patient with an immediately life-threatening condition can gain access to the drug.

The company is ready to launch the product this month if approval is given.

Published on April 26, 2021

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.